A network FDA funds, not FDA runs

FDA Radar’s four sources are all, in one sense, the same kind of object: a federal agency publishing its own record, on its own schedule, in a structured place a script can read. FDA runs a program built on a different premise entirely — it paid to create a real-world-evidence network for medical devices, then handed that network’s governance to a private consortium that owes the public none of the structure FDA’s own record does.

A cooperative agreement, not an office

In August 2016, FDA’s Center for Devices and Radiological Health awarded a cooperative agreement — not a contract, not a new internal office — to the Medical Device Innovation Consortium (MDIC), the same public-private consortium behind the Case for Quality program’s Voluntary Improvement Program. The award established a Coordinating Center for what FDA calls the National Evaluation System for health Technology (NEST): NESTcc. NESTcc governs the NEST ecosystem, builds its infrastructure, sets its data standards, and reports on its progress. It is not a division of FDA, and it was never meant to become one.

What FDA actually bought

NEST’s job, in FDA’s own description, is to link and synthesize real-world data — clinical registries, electronic health records, medical billing claims, patient-mediated data — into evidence FDA can use across a device’s total product lifecycle, not only at clearance. Funding for the build-out stepped up through FDA’s MDUFA IV commitment letter, the device-user-fee agreement covering fiscal years 2018 through 2022, in which FDA committed to running a pilot demonstrating real-world evidence’s value and to expanding its own expertise alongside NESTcc’s growth. A user-fee negotiation, not a rule, is what actually pays for the pipes.

The Marketplace, and what never crosses into it

In May 2024, NESTcc launched the NEST Medical Device RWE Marketplace — a platform matching device sponsors against data and research partners for the studies NEST is built to support: label-expansion studies, postmarket safety studies, synthetic or historical control groups standing in for a second clinical arm, objective performance criteria a whole product category can be measured against. A sponsor lists a need; a data partner takes the engagement; a study runs. None of that listing, contracting, or running is a federal action. NESTcc is a private consortium operating under a cooperative agreement, not a component of FDA — its own records are not government records the way a warning letter or a Federal Register notice is, and nothing compels it to disclose what it is doing the way FDA’s own reporting rules compel a manufacturer to report a malfunction.

FDA paid to build the pipes. What runs through them belongs to whoever paid for the study.

The practice

A portfolio watch reading Federal Register notices, warning letters, enforcement reports, and 510(k) clearances against a product code or a firm name will never see a NEST engagement while it is running, because none of FDA Radar’s four sources was ever positioned to. If a study run through NEST eventually supports a label expansion or a postmarket commitment, its result can surface later inside a submission’s own summary language — and even then, nothing in that summary is structured to say the evidence came from NEST specifically. Whether a competitor is running a NEST-backed study against your predicate’s product code right now is a question for the Marketplace itself, published literature, or a company’s own announcements, not a question any public regulatory database was built to answer. This is regulatory intelligence and method, never regulatory advice about what a specific real-world-evidence study should carry, or whether one is running against a device that matters to you.